Memantine: Nursing Drug Guide, Renal Dosing & NCLEX Review
Memantine is cleared in urine—severe renal impairment and alkaline urine (sodium bicarbonate, carbonic anhydrase inhibitors) can raise levels and trigger dizziness, confusion, and hallucinations. Verify CrCl-based dosing, weekly 5 mg titration to 20 mg/day, and never double a missed dose.
Hold and escalate for new or worsening confusion, hallucinations, or dizziness—especially when CrCl is 5–29 mL/min but the patient receives more than 5 mg twice daily, or when urine-alkalinizing drugs start. Rapid titration without weekly steps also raises CNS toxicity risk in older adults with dementia.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before each dose, confirm renal function, current memantine strength and schedule, and any new alkaline urine medicines. If the patient develops dizziness, confusion, or hallucinations, hold memantine and notify the prescriber or pharmacist—do not double missed doses or restart at full strength after several missed days without retitration.
Most common brand names
Immediate-release tablets (5 mg, 10 mg) and extended-release capsules are available. Strength and color differ by product—always verify the milligram strength and formulation on the label before administration.
Common U.S. brand names include Namenda, Namenda XR, and generic memantine hydrochloride. Fixed-dose combination products containing memantine with donepezil are also marketed—treat each component as a separate medicine for dosing and safety checks.
Why we give it — Indications
Per U.S. prescribing information, memantine is an NMDA receptor antagonist indicated for treatment of moderate to severe dementia of the Alzheimer’s type. It is not a cure—it may modestly slow decline in some patients when tolerated.
| Use | Detail |
|---|---|
| Alzheimer’s dementia (moderate–severe) | Primary labeled indication; efficacy demonstrated in controlled trials at 20 mg/day maintenance |
| Combination therapy | May be co-prescribed with a cholinesterase inhibitor per prescriber plan—pharmacokinetic interaction with donepezil is minimal, but monitor cumulative CNS effects |
| Goals of care | Support cognition and function while monitoring renal dosing, urine pH effects, and neuropsychiatric adverse events—not for acute delirium reversal alone |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Memantine is a low-to-moderate affinity uncompetitive NMDA receptor antagonist that may reduce glutamatergic excitotoxicity thought to contribute to Alzheimer’s pathology. It is eliminated largely unchanged in urine via glomerular filtration and active tubular secretion, with pH-dependent tubular reabsorption—so renal function and urine alkalinity directly affect plasma levels and CNS adverse effects.
Dosing overview
May be taken with or without food. Increase dose in 5 mg weekly steps with at least 1 week on each prior dose before escalating.
| Scenario | Dose adjustment (labeling) |
|---|---|
| Mild renal impairment | No dosage adjustment recommended |
| Moderate renal impairment | No dosage adjustment recommended; mean AUC increased about 60% in pharmacokinetic study—monitor clinically |
| Severe renal impairment (CrCl 5–29 mL/min) | Target dose 5 mg twice daily—verify serum creatinine and eGFR/CrCl before each titration step |
| Hepatic impairment | No adjustment for mild–moderate; use caution in severe hepatic impairment (not studied) |
| Missed dose | Take next scheduled dose—do not double. If missed for several days, resume at lower doses and retitrate per prescribing information |
| Pediatrics | Not established for Alzheimer’s indication; pediatric ASD trials did not demonstrate efficacy |
On a small screen, swipe or scroll sideways to see the full table.
Missed dose: If one dose is missed, give the next scheduled dose when due—never take two doses at once. After several missed days, contact the prescriber or pharmacist before restarting at full maintenance strength; retitration from 5 mg daily may be required.
Before you give it — Safety check
Pretreatment checks
- Complete medication reconciliation—renal dose, urine-alkalinizing agents, and other NMDA antagonists
- Confirm allergy history: hypersensitivity to memantine hydrochloride or formulation excipients only
- Baseline renal function (CrCl/eGFR) and plan for repeat checks before each weekly titration
- Review carbonic anhydrase inhibitors, sodium bicarbonate, and conditions that alkalinize urine
- Screen for overlapping NMDA antagonists (amantadine, dextromethorphan, ketamine)
- Assess baseline cognition, fall risk, and behavioral symptoms to detect drug-related worsening
Contraindications
- Known hypersensitivity to memantine hydrochloride or any excipients in the formulation
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Drugs that alkalinize urine | Carbonic anhydrase inhibitors, sodium bicarbonate—clearance reduced about 80% at urine pH 8; accumulation increases CNS adverse effects | Flag new starts; monitor for dizziness, confusion, hallucinations; pharmacy review |
| Other NMDA antagonists | Amantadine, ketamine, dextromethorphan—combined use not systematically evaluated | Reconcile OTC cough/cold products; question duplicate mechanisms |
| Renal cationic drugs | Hydrochlorothiazide, triamterene, metformin, cimetidine, ranitidine, quinidine, nicotine—shared tubular secretion may alter levels | Pharmacy review when new diuretic or antihyperglycemic starts; trend renal function |
| Cholinesterase inhibitors | No pharmacokinetic interaction with donepezil; combination adverse-event profile similar to donepezil alone in trials | Still monitor cumulative GI and CNS effects in practice |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral route: Immediate-release tablets or extended-release capsules per order. May take with or without food.
- Immediate-release: swallow tablets whole with water unless pharmacy provides an alternate formulation
- Extended-release (Namenda XR): swallow capsule whole—do not divide, crush, or chew unless pharmacy converts
- Split daily doses when titrating through 15 mg/day (5 mg + 10 mg as separate doses) before 10 mg BID maintenance
- Use medication administration five-rights; independent double-check when strength or schedule changes
Conditions that raise urine pH decrease urinary elimination and can increase memantine plasma levels. Reconcile antacids, bicarbonate therapy, and carbonic anhydrase inhibitors on admission and after transfers—especially when CNS symptoms emerge.
Expected therapeutic response
- Gradual stabilization or modest improvement in cognition, communication, or daily function over weeks to months—not immediate
- Mild dizziness or headache may occur early and often resolve without dose change when titration is appropriate
- Absence of new confusion, hallucinations, or gait instability after dose increases or new urine-alkalinizing drugs
- Caregiver reports of safer participation in ADLs when therapy is tolerated at renal-appropriate doses
Red flags — Stop and act
Escalate immediately for CNS toxicity suggesting accumulation, overdose, or unsafe dosing in renal impairment.
- New or worsening confusion, hallucinations, or psychosis—especially after sodium bicarbonate, carbonic anhydrase inhibitors, or dose above renal limits
- Severe dizziness, vertigo, or unsteady gait with fall risk
- Memantine 10 mg twice daily when CrCl is 5–29 mL/min (maximum should be 5 mg twice daily)
- Agitation, restlessness, or combativeness that is acute and temporally linked to dosing or interactions
- Suspected overdose—agitation, confusion, coma, bradycardia, hypertension, stupor, visual hallucinations, vomiting, weakness
- Rapid titration without weekly 5 mg steps or restart at full dose after prolonged omission
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Dizziness | ≥5% and higher than placebo (7% vs 5%) | Fall precautions; hold and notify if severe or with gait change |
| Headache | ≥5% and higher than placebo (6% vs 5%) | Document; differentiate from other causes; support comfort measures |
| Confusion | ≥5% and higher than placebo (6% vs 5%) | Assess delirium triggers; hold if acute worsening; renal and urine pH review |
| Constipation | ≥5% and higher than placebo (5% vs 4%) | Bowel regimen; hydration; monitor with anticholinergic co-meds |
| Hallucination | 2–3% in trials; higher with accumulation | Hold memantine; notify prescriber; safety supervision |
| Agitation, anxiety, fatigue | ≥2% in trials; postmarketing CNS and psychiatric reports | Behavior log; avoid sedative stacking without review; escalate if self-harm risk |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Overdosage may cause agitation, asthenia, bradycardia, confusion, coma, dizziness, hypertension, lethargy, psychosis, somnolence, stupor, unsteady gait, visual hallucinations, vertigo, vomiting, and weakness. No specific antidote is listed.
Management (labeling)
- General supportive measures; contact local poison control / toxicology per facility protocol
- Symptomatic treatment; monitor airway, perfusion, and neurologic status
- Urine acidification may enhance elimination per U.S. prescribing information—coordinate with medical toxicology
- Do not rely on dialysis alone—memantine has low protein binding but elimination is pH-dependent
Contact local poison control or medical toxicology services per facility protocol and local emergency guidance for suspected overdose—especially with altered consciousness, hemodynamic instability, or seizures.
Look-alike / sound-alike and error prevention
- Memantine vs amantadine—both affect NMDA pathways; read back full generic name
- 5 mg vs 10 mg—debossing and color vary by brand; verify strength at each administration
- Once daily vs twice daily—common error during titration weeks or renal adjustment
- Full 20 mg/day in severe renal impairment—should be 5 mg BID only
- Restart after missed days—do not resume full maintenance without prescriber/pharmacy retitration plan
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| CrCl check before titration | Flag MAR when weekly +5 mg step is due—confirm renal category still matches dose |
| Urine pH drugs | New sodium bicarbonate or acetazolamide order → notify pharmacy; watch CNS symptoms 24–72 h |
| Titration calendar | Minimum 7 days per dose level before increase to next 5 mg step |
| Commonly missed | OTC dextromethorphan; duplicate memantine in combination product plus separate order |
| Ask pharmacy when | Feeding-tube formulation, severe renal dose unclear, or restart after prolonged omission |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults (typical patient) | Mean trial age ~76 years; accumulation from renal impairment or alkaline urine increases dizziness and confusion—fall precautions |
| Severe renal impairment (CrCl 5–29) | Limit to 5 mg BID—higher exposure and longer half-life vs healthy subjects |
| Moderate renal impairment | No labeled adjustment but ~60% higher AUC—closer CNS monitoring |
| Alkaline urine states | Carbonic anhydrase inhibitors, bicarbonate, renal tubular acidosis, severe UTI—reduced clearance |
| Genitourinary conditions | Conditions raising urine pH may increase levels—relevant to urinary incontinence workups and alkalinizing therapy |
| Severe hepatic impairment | Not studied—administer with caution per labeling |
| Pregnancy / lactation | Limited human data—use only if benefit justifies risk; breastfeeding decision individualized |
| Pediatrics | Not indicated for Alzheimer’s; ASD trials did not show efficacy |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Renal function (creatinine, CrCl/eGFR) before initiation and before each titration step
- Mental status, behavior, hallucinations, dizziness, and gait—especially after dose changes or new urine-alkalinizing drugs
- Fall and injury surveillance on memory-care units
- Medication list for NMDA antagonists, bicarbonate, carbonic anhydrase inhibitors, and renal cationic drugs
- Bowel pattern when constipation reported
Document
- Strength, schedule (once daily vs BID), formulation (IR vs XR), and titration milestone dates
- CrCl category supporting current dose; pharmacy verification for severe renal impairment
- Hold events with prescriber/pharmacist notification and CNS reassessment
- Caregiver teaching on missed-dose rules and when to report confusion or hallucinations
Patient teaching
- Take exactly as prescribed—do not double a missed dose
- If several doses were missed, call the prescriber or pharmacist before restarting—may need to start low and increase slowly again
- Report new dizziness, confusion, seeing or hearing things that are not there, or unsteady walking immediately
- Share all medicines including antacids, bicarbonate, cough/cold products, and diuretics
- Swallow extended-release capsules whole unless the pharmacist gave different instructions
- Caregivers should supervise dosing and watch for falls after any dose increase
The Hold Rule
Do not give and contact the prescriber or pharmacist when:
- Known hypersensitivity to memantine or formulation excipients
- New or worsening confusion, hallucinations, severe dizziness, or psychosis suggesting accumulation
- Dose exceeds renal limits (e.g., 10 mg BID when CrCl 5–29 mL/min)
- New sodium bicarbonate or carbonic anhydrase inhibitor without renal-dose review
- Unsafe titration (less than 1 week on prior dose) or order to restart full strength after prolonged omission
- Prescriber direction to discontinue for intolerance or suspected toxicity
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
On memory-care units, memantine is often continued from home without a current CrCl or urine pH medication review. Pair weekly titration checks with renal dosing verification and surveillance for CNS toxicity when alkalinizing drugs start.
1. Check-before-you-give protocol
- Right patient, drug, strength, schedule, and formulation (IR vs XR)
- CrCl category matches dose (5 mg BID if severe renal impairment)
- No new urine-alkalinizing or duplicate NMDA antagonist medicines
- No active confusion, hallucinations, or severe dizziness since last dose
2. High-alert and safety badge
Not a universal high-alert drugRenal overdose dosing and urine alkalinization errors can still cause serious CNS toxicity—use independent verification when titrating or restarting therapy.
3. Clinical workflow: hold and question rules
- If CrCl 5–29 and order is 10 mg BID, hold and clarify with pharmacy before administering
- If sodium bicarbonate starts and patient becomes acutely confused, hold memantine and notify prescriber
- If patient missed therapy for several days, hold full maintenance restart until retitration plan confirmed
4. Critical teach-back questions
- “What should you do if you miss one dose?” (Take the next scheduled dose only—do not double.)
- “When should you call the care team about this medicine?” (New confusion, hallucinations, severe dizziness, or falls.)
5. Care coordination
Pharmacist: Renal dose verification, urine pH interaction review, retitration after omissions, overdose guidance
Prescriber / memory-care team: Cognition goals, behavioral symptoms, hold parameters, and combination therapy plans
🧠 Quick mental checklist
- CrCl checked and dose matches renal category?
- Weekly +5 mg titration interval met?
- Any new bicarbonate or carbonic anhydrase inhibitor?
- New confusion, hallucinations, or severe dizziness?
- Missed-dose plan—no double dose; retitrate if several days missed?
Memantine NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for memantine with a tabbed memory-care case (MAR, labs, history, nursing notes), then priority action, renal and urine pH cue recognition, deterioration trends, matrix urgency, missed-dose safety, and renal-dose documentation cloze—recognize cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Memantine 10 mg PO twice daily — ongoing (home regimen continued on admission)
- Sodium bicarbonate 650 mg PO BID — started yesterday for metabolic acidosis
- Acetazolamide 250 mg PO daily — resumed this morning per nephrology
- Lisinopril 5 mg PO daily — unchanged
- Hydrochlorothiazide 12.5 mg PO daily — unchanged
- Creatinine 2.1 mg/dL (baseline 1.8 six months ago)
- CrCl 22 mL/min (Cockcroft-Gault) — severe renal impairment category
- BUN 38 mg/dL, K 4.2 mmol/L, Na 138 mmol/L
- CO2 18 mmol/L yesterday → bicarbonate started
- No serum memantine level ordered (not routine)
- 79-year-old with moderate Alzheimer’s disease; lives with daughter
- CKD stage 4; nephrology follows quarterly
- Memantine titrated to 10 mg BID at another facility six months ago when creatinine was higher but CrCl not recalculated on transfer
- No known memantine allergy
- Daughter reports patient was stable until bicarbonate started
- Admitted 48 h ago from assisted living; fall precautions in place
- Overnight: patient talking to empty chair, picking at bedding, disoriented to place
- Today 0900: dizzy when transferring; assisted back to bed
- Behavioral chart: increased restlessness and calling out — new since bicarbonate
- Pharmacy note pending renal dose review
Answer key & rationale
Frequently asked questions
Why is renal dosing the main nursing concern with memantine?
Memantine is eliminated largely unchanged in urine. Severe renal impairment (creatinine clearance 5–29 mL/min) requires a target dose of 5 mg twice daily instead of the usual 20 mg/day maintenance dose. Accumulation raises the risk of dizziness, confusion, and hallucinations.
How does urine pH affect memantine levels?
Alkaline urine decreases urinary elimination of memantine—clearance was reduced about 80% at urine pH 8 in labeling. Carbonic anhydrase inhibitors, sodium bicarbonate, and some clinical states that alkalinize urine can increase plasma levels and CNS adverse effects.
When should nurses hold memantine?
Hold for known hypersensitivity; new or worsening confusion, hallucinations, or dizziness suggesting accumulation; dose above renal limits; unsafe rapid titration; or prescriber direction. Reconcile alkaline urine drugs and other NMDA antagonists before restarting.
What should patients do if they miss memantine doses?
If a single dose is missed, take the next scheduled dose—do not double up. If memantine is missed for several days, dosing may need to resume at lower doses and be retitrated per prescribing information.
Is there an antidote for memantine overdose?
No specific antidote is listed. Management is supportive; contact local poison control or medical toxicology per facility protocol. Elimination may be enhanced by urine acidification per U.S. prescribing information.
References
-
U.S. National Library of Medicine. NAMENDA (memantine hydrochloride) — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9f27baf-aa2a-443a-9ef5-e002d23407ba
-
National Library of Medicine. MedlinePlus: Memantine.https://medlineplus.gov/druginfo/meds/a604006.html
-
Drugs and Lactation Database (LactMed). Memantine. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK556032/
-
U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program.https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
-
National Institute on Aging. Alzheimer’s Disease Medications Fact Sheet. NIH.https://www.nia.nih.gov/health/alzheimers-treatment/how-alzheimers-disease-treated
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.